Evidence map›Paper›PMID 41114339›Full record

ArticleFrontiers in oncology2025

CT-based radiomics and deep learning to predict EGFR mutation status in lung adenocarcinoma.

Xingzhi Jiang, Qian Sun, Can Wang, Wei Li, Wang Chen, Juan Xu, Lei Yu

Abstract read
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xingzhi JiangDepartment of Respiratory Medicine, the First People's Hospital of Yancheng, Yancheng, China.
Qian SunDepartment of Respiratory Medicine, the First People's Hospital of Yancheng, Yancheng, China.
Can WangDepartment of Respiratory Medicine, the First People's Hospital of Yancheng, Yancheng, China.
Wei LiDepartment of Respiratory Medicine, the First People's Hospital of Yancheng, Yancheng, China.
Wang ChenDepartment of Radiology, the First People's Hospital of Yancheng, Yancheng, China.
Juan XuDepartment of Respiratory Medicine, the First People's Hospital of Yancheng, Yancheng, China.
Lei YuDepartment of Radiology, the First People's Hospital of Yancheng, Yancheng, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Epidermal growth factor receptor (EGFR) mutation status is an essential biomarker guiding targeted therapy selection in lung adenocarcinoma. This study aimed to develop and validate a non-invasive predictive model that integrates radiomics and deep learning using CT images for accurate assessment of EGFR mutation status. Methods: A total of 220 patients with lung adenocarcinoma were retrospectively enrolled and randomly divided into training and testing cohorts at a 7:3 ratio. Radiomics features were extracted from CT images using PyRadiomics, and deep learning features were obtained from five pretrained architectures: ResNet34, ResNet152, DenseNet121, ShuffleNet, and Vision Transformer (ViT). Feature selection used the intraclass correlation coefficient, Spearman correlation, and LASSO regression. The deep learning architectures were compared within the training set using cross-validation, and the best-performing architecture, ViT, was retained for downstream modeling. Based on the selected features, we constructed a radiomics model (Rad model), a ViT-based deep learning model (ViT model), and two fusion models (early fusion and late fusion) integrating radiomics and ViT features. Model performance was evaluated using receiver operating characteristic (ROC) curves, area under the curve (AUC), accuracy, sensitivity, specificity, precision, F1-score, and decision curve analysis (DCA). Results: The fusion models outperformed both radiomics and deep learning models in predicting EGFR mutation status. In the testing set, the early fusion model achieved the highest predictive performance (AUC = 0.910), exceeding the late fusion model (AUC = 0.892), the ViT model (AUC = 0.870), and the Rad model (AUC = 0.792). It also demonstrated superior accuracy (0.848), sensitivity (0.872), and specificity (0.815). Decision curve analysis further confirmed its clinical utility. Conclusion: Our study demonstrated that integrating radiomics and deep learning contributed to EGFR mutation prediction, providing a non-invasive approach to support personalized treatment decisions in lung adenocarcinoma.

Indexed as

CTdeep learningEGFRfusion modellung adenocarcinomaradiomics

Identifiers

PMID41114339
PMCPMC12527853

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.